8-K: SeaStar Medical Reports 82% Revenue Growth, Trial Progress

SeaStar Medical announced Q2 2026 financial results, showcasing an 82% increase in QUELIMMUNE net revenue and advancements in its NEUTRALIZE-AKI trial, alongside obtaining crucial billing codes.

Summary

• SeaStar Medical reported Q2 2026 net revenue of $0.6 million, an 82% increase compared to $0.3 million in Q2 2025, driven by QUELIMMUNE product sales.
• The company added 3 new children's hospitals to its QUELIMMUNE customer base, bringing the total to 20.
• Enrollment in the NEUTRALIZE-AKI pivotal clinical trial for adult AKI patients has reached 223 out of a target of 339.
• SeaStar Medical obtained ICD-10-PCS codes for its selective cytopheretic device (SCD) therapy, facilitating inpatient hospital billing, effective October 1, 2026.
• Net loss for Q2 2026 was $3.7 million ($0.91 per share), compared to a net loss of $2.0 million ($1.77 per share) in Q2 2025.
• Cash reserves stood at $7.0 million as of June 30, 2026, down from $12.0 million at December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting significant revenue growth and progress in clinical trials, though net losses persist.

Positives

• Significant 82% year-over-year net revenue growth for QUELIMMUNE, reaching $0.6 million in Q2 2026.
• Expansion of the QUELIMMUNE customer base to 20, including 3 new top-rated children's hospitals.
• Advancement in the NEUTRALIZE-AKI trial, with 223 out of 339 adult AKI patients enrolled.
• Secured dedicated ICD-10-PCS codes for SCD therapy, which are expected to enable standardized inpatient hospital billing starting October 1, 2026.
• Strong gross margins for QUELIMMUNE, reported at 91% for Q2 2026.
• Published data showing a 76-77% survival rate for QUELIMMUNE treated patients in clinical trials, representing a significant reduction in mortality compared to historical data.

Negatives

• Net loss increased to $3.7 million in Q2 2026 from $2.0 million in Q2 2025.
• Cash balance decreased to $7.0 million from $12.0 million over six months.
• Research and development expenses more than doubled to $2.5 million in Q2 2026 from $1.0 million in Q2 2025, primarily due to increased clinical trial costs.
• General and administrative expenses also increased significantly to $1.8 million from $1.0 million, attributed to compensation, legal fees, and SEC-related expenses.

Risks

• The risk of not obtaining regulatory approval for SCD product candidates.
• The risk of not being able to raise sufficient capital to fund operations and clinical trials.
• The risk of delays in product development and commercialization.
• The risk of not achieving or sustaining profitability.
• The risk of third-party suppliers and manufacturers not meeting their obligations.
• The risk of product liability or regulatory lawsuits.
• The risk of being unable to secure or protect intellectual property.

Future Outlook

The company anticipates completing enrollment in the NEUTRALIZE-AKI trial around year-end 2026 or early Q1 2027, potentially enabling a PMA application to the FDA by the end of 2027. Management expresses confidence in the future potential of QUELIMMUNE and the adult AKI market, emphasizing the value creation potential upon FDA approval.

Management Comments

• "The enthusiasm for the use of our QUELIMMUNE therapy is resonating broadly throughout the pediatric critical care community."
• "We believe our continued QUELIMMUNE revenue growth bodes well for our future potential opportunity in the adult AKI market that is 50 times larger than the current pediatric market in the U.S."
• "We are keenly focused on achieving our enrollment target of 339 adult AKI patients in the NEUTRALIZE-AKI trial, and we are working with the FDA on our modular Premarket Approval (PMA) application for our SCD therapy as an organ-sparing and life-saving treatment for the adult patient population."
• "With strong gross margins for QUELIMMUNE and universal ICD-10-PCS codes already established for our SCD therapies, we believe this first-in-class therapy for the treatment of adult patients with AKI has clear potential to both save lives and create significant shareholder value, should we obtain FDA approval."

Industry Context

StockSavvy.ai notes that SeaStar Medical's progress aligns with a growing focus on innovative treatments for critical care conditions like Acute Kidney Injury (AKI). The company's strategy to leverage its pediatric success (QUELIMMUNE) into the larger adult AKI market is a common, albeit challenging, path for medical device companies. The acquisition of dedicated billing codes is a crucial step for commercial adoption in the U.S. healthcare system.

Stakeholder Impact

• Shareholders: Potential for future value creation if clinical trials are successful and FDA approval is obtained, but current results show increased losses and decreased cash reserves.
• Patients: Continued access to QUELIMMUNE for pediatric AKI and potential future access to SCD therapy for adult AKI, with improved survival rates and kidney function noted in trials.
• Hospitals/Healthcare Providers: Facilitation of billing for SCD therapy through new ICD-10-PCS codes, potentially increasing adoption.
• Creditors: The decrease in cash reserves may raise concerns about the company's ability to fund ongoing operations without additional capital.

Next Steps

• Continue enrollment in the NEUTRALIZE-AKI pivotal clinical trial.
• Work with the FDA on the modular Premarket Approval (PMA) application for SCD therapy in adults.
• Anticipate the effective date of ICD-10-PCS codes on October 1, 2026, for billing purposes.
• Prepare for webcast and conference call to discuss Q2 2026 results.

Key Dates

Recommendation

The company shows promising revenue growth and clinical progress, particularly with the new billing codes. However, the increasing net loss and decreasing cash balance, coupled with the long timeline to potential FDA approval for the adult indication, warrant a cautious 'hold' stance. Further de-risking of the clinical trial and regulatory pathway is needed for a more positive outlook.

Keywords

Acute Kidney Injury, AKI, QUELIMMUNE, SCD therapy, NEUTRALIZE-AKI trial, pediatric critical care, healthcare, medical device